Daily Stock Analysis, BLCM, Bellicum Pharmaceuticals Inc, priceseries

Bellicum Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
13.43
Close
12.12
High
13.69
Low
11.97
Previous Close
12.79
Daily Price Gain
-0.67
YTD High
14.84
YTD High Date
Jan 5, 2017
YTD Low
11.65
YTD Low Date
Jan 31, 2017
YTD Price Change
-1.77
YTD Gain
-12.74%
52 Week High
23.11
52 Week High Date
Nov 14, 2016
52 Week Low
7.24
52 Week Low Date
Mar 17, 2016
52 Week Price Change
2.34
52 Week Gain
23.93%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 6. 2015
16.39
Dec 4. 2015
21.98
19 Trading Days
34.08%
Link
LONG
Mar 29. 2016
8.64
Apr 19. 2016
10.84
15 Trading Days
25.49%
Link
LONG
May 20. 2016
10.16
Jun 13. 2016
12.60
15 Trading Days
23.97%
Link
LONG
Jun 29. 2016
12.64
Jul 13. 2016
13.92
9 Trading Days
10.14%
Link
LONG
Jul 25. 2016
14.51
Aug 18. 2016
18.67
18 Trading Days
28.64%
Link
LONG
Nov 9. 2016
19.28
Nov 22. 2016
21.39
9 Trading Days
10.94%
Link
Company Information
Stock Symbol
BLCM
Exchange
NasdaqGM
Company URL
http://www.bellicum.com
Company Phone
(832) 384-1100
CEO
Thomas J. Farrell
Headquarters
Texas
Business Address
2130 WEST HOLCOMBE BOULEVARD, SUITE 800, HOUSTON, TX 77030
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001358403
About

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the ...

Description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a chimeric antigen receptor (CAR-T) product candidate for treating solid tumors expressing the prostate stem cell antigen; BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma; and BPX-401, a CAR-T product candidate for the treatment of hematological cancers that express the CD19 antigen. The company has a research collaboration agreement with Holland's Leiden University Medical Center to discover and validate natural high-affinity T cell receptor product candidates targeting various cancers. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.